Qingdao hUC-MSC-sEV-003 SSNHL study
Also known as: Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss, Clinical Phase I and IIa Trials of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss, hUC-MSC-sEV-003, Tympanic injection of hUC-MSC-sEV-003 small extracellular vesicles, Standard treatment for sudden deafness plus hUC-MSC-sEV-003, Standard treatment for sudden deafness plus dexamethasone, NCT07404709
Institution-led study
Not-yet-recruiting Phase 1/2 study evaluating intratympanic hUC-MSC-sEV-003 small extracellular vesicles derived from mesenchymal stem cells for severe or profound sudden sensorineural hearing loss, with dose exploration followed by comparison against dexamethasone control.
Promoted as a verified institution-led Phase 1/2 study. The linked registry describes hUC-MSC-sEV-003 dose exploration and a Phase IIa standard-treatment comparison; generated dose and standard-treatment arms should remain collapsed into this study-level record.